Compare · AMRN vs LLY
AMRN vs LLY
Side-by-side comparison of Amarin Corporation plc (AMRN) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMRN and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 3885.4x AMRN ($298.9M).
- Over the past year, AMRN is down 7.2% and LLY is up 61.6% - LLY leads by 68.9 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 3 for AMRN).
- LLY has more recent analyst coverage (25 ratings vs 11 for AMRN).
- Company
- Amarin Corporation plc
- Eli Lilly and Company
- Price
- $14.43+1.80%
- $1189.35-3.57%
- Market cap
- $298.9M
- $1.16T
- 1M return
- +3.33%
- -2.65%
- 1Y return
- -7.23%
- +61.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 17
- Recent ratings
- 11
- 25
Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest AMRN
- New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
- Analyst resumed coverage on Amarin with a new price target
- SVP, CFO Fishman Peter L. converted options into 313 units of American Depositary Share and covered exercise/tax liability with 155 units of American Depositary Share, increasing direct ownership by 2% to 7,619 units (SEC Form 4)
- SEC Form 10-Q filed by Amarin Corporation plc
- Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition
- Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
- EVP, Chief Scientific Officer Ketchum Steven B converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,887 units of American Depositary Shares, increasing direct ownership by 4% to 42,680 units (SEC Form 4)
- EVP, Chief Operating Officer Keenan David Paul converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,926 units of American Depositary Shares, increasing direct ownership by 15% to 13,470 units (SEC Form 4)
- SVP, CFO Fishman Peter L. converted options into 2,447 units of American Depositary Shares and covered exercise/tax liability with 1,206 units of American Depositary Shares, increasing direct ownership by 20% to 7,461 units (SEC Form 4)
- EVP, Chief Legal Officer Provoost Jonathan converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,264 units of American Depositary Shares, increasing direct ownership by 110% to 4,624 units (SEC Form 4)
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market